Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 94.5% in May

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) saw a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 531,500 shares, a decline of 94.5% from the May 15th total of 9,710,000 shares. Based on an average daily trading volume, of 92,600 shares, the days-to-cover ratio is currently 5.7 days. Currently, 8.8% of the company's shares are short sold.

Insider Transactions at Lyell Immunopharma

In other news, CFO Charles W. Newton acquired 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $11.20 per share, for a total transaction of $112,000.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at $112,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders acquired a total of 21,782 shares of company stock worth $247,958 in the last quarter. 22.30% of the stock is owned by company insiders.

Institutional Trading of Lyell Immunopharma

A number of institutional investors have recently made changes to their positions in LYEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Lyell Immunopharma by 13.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company's stock worth $197,000 after buying an additional 36,555 shares during the last quarter. Takeda Pharmaceutical Co. Ltd. acquired a new position in Lyell Immunopharma during the fourth quarter worth $527,000. BNP Paribas Financial Markets acquired a new position in Lyell Immunopharma during the fourth quarter worth $162,000. Johnson & Johnson acquired a new position in Lyell Immunopharma during the fourth quarter worth $527,000. Finally, SG Americas Securities LLC increased its holdings in Lyell Immunopharma by 102.8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock worth $75,000 after buying an additional 59,182 shares during the last quarter. Institutional investors own 66.05% of the company's stock.

Analyst Upgrades and Downgrades

LYEL has been the topic of a number of research reports. Wall Street Zen raised shares of Lyell Immunopharma to a "hold" rating in a research note on Friday, June 6th. HC Wainwright reissued a "neutral" rating and issued a $20.00 price objective on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

Lyell Immunopharma Stock Performance

Shares of LYEL stock remained flat at $9.74 during trading on Friday. 76,722 shares of the stock were exchanged, compared to its average volume of 67,593. The firm's 50 day moving average is $9.00 and its two-hundred day moving average is $11.59. The stock has a market capitalization of $144.23 million, a P/E ratio of -12.33 and a beta of -0.26. Lyell Immunopharma has a twelve month low of $7.65 and a twelve month high of $47.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($3.60) EPS for the quarter, topping analysts' consensus estimates of ($3.80) by $0.20. The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, equities analysts forecast that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.